

PCT/EP03/10064 A 3058



10/527346

Amended Claims

DT15 Rec'd PCT/PTO 0 9 MAR 2005

(1-Oct-04)

- 1. A bivalent or multivalent antibody characterized by the following features:
 - (a) it is capable of supressing an immune reaction;
 - (b) it is devoid of constant antibody regions; and
 - (c) it binds an epitope on the CD3 complex of the T-cell receptor.
- 2. The antibody of claim 1 that is a diabody.
- 3. The antibody of claim 1 that comprises two scFv antibodies linked by a peptide linker.
- 4. The antibody of claim 1 that is a single chain diabody.
- 5. The antibody according to any one of claims 1 to 4, wherein the variable V_{H} and V_{L} domains are connected via the peptide linker SAKTTP or SAKTTPKLGG.
- 6. The antibody according to any one of claims 1 to 5 wherein the variable domains correspond to the variable domains of the antibody produced by the hybridoma of ATCC deposit number CRL 8001.
- 7. The antibody according to claim 6, wherein a cysteine at position H100A (Kabat numbering system) has been exchanged for another amino acid.
- 8. The antibody according to claim 7, wherein the cysteine has been exchanged for a serine.
- 9. A polynucleotide, which encodes an antibody of any one of claims 1 to 8.



Ģ

PCT/EP03/10064 A 3058



- 10. An expression vector comprising the polynucleotide of claim 9.
- 11. The expression vector of claim 10, which is pSKK3-scFv 6anti-CD3 (DSM 15137).
- 12. A host cell containing the expression vector of claim 10 or 11.
- 13. A pharmaceutical composition containing the antibody of any one of claims 1 to 8, the polynucleotide of claim 9 or the expression vector of claim 10 or 11.
- 14. Use of an antibody which is characterized by the following features:
 - (a) it is capable of supressing an immune reaction;
 - (b) it is devoid of constant antibody regions; and
 - (c) it binds an epitope on the CD3 complex of the T-cell receptor; or the polynucleotide of claim 9 or expression vector of claim 10 or 11 for the preparation of a pharmaceutical composition for immunotherapy.
- 15. Use according to claim 14, wherein the antibody is antibody of any one of claims 1 to 8.
- 16. Use according to claim 14 or 15, wherein immunotherapy is a therapy against acute rejections.
- Use of the polynucleotide of claim 9 or the expression of claim or 11 for the preparation of pharmaceutical composition for gene therapy.